Cancer Incidence and Mortality in Osaka, Japan: Future Trends Estimation with an Age-Period-Cohort Model

Mai Utada1*, Yuko Ohno1, Sachiko Shimizu1, Yuri Ito2, Hideaki Tsukuma2

Abstract

In previous studies we predicted future trends in cancer incidence for each prefecture in order to plan cancer control. Those predictions, however, did not take into account the characteristics of each prefecture. We therefore used the results of age-period-cohort analysis of incidence and mortality data of Osaka, and estimated the incidence and mortality of cancers at all sites and selected sites. The results reflect the characteristics of Osaka, which has and is expected to have large numbers of patients with liver cancer. We believe our results to be useful for planning and evaluating cancer control activities in Osaka. It would be worthwhile to base the estimation of cancer incidence and mortality in each prefecture on population-based cancer registry.

Keywords: Cancer incidence and mortality - estimation - age-period-cohort model - Japan

Introduction

Estimated future trends in cancer incidence and mortality are important in the planning of cancer control policy and in the evaluation of the cancer control activities. In previous studies we predicted the numbers of incident cases of major cancers in all of Japan (Utada et al., 2010a) and in each of Japan’s prefectures based on cancer incidence data for all of Japan (Utada et al., 2010b). Although those predicted incidences reflect the population composition and relative degrees of changes in each prefecture, they were estimated without considering characteristics of each prefecture, even though the incidence rates for cancers at certain sites differ between regions (National Cancer Center, 2006). The subjects of the previous estimation were people aged 89 and under, therefore the number of cancers incident in people aged 90 or older was not considered. Japan is rapidly aging, so we believe that the number of cancer incident in people aged 90 or more years old is not negligible.

In this study we estimated the future cancer incidence and cancer mortality reflecting Osaka characteristics for people of all ages in Osaka. Osaka is one of the largest prefectures in Japan, therefore we believe the result of this study would be useful for planning cancer control policy not only for Osaka but also for all of Japan.

Materials and Methods

Data sources and projection methods

We used an age-period-cohort (APC) model to estimate cancer incidence and mortality as in previous studies (Ohno et al., 2004; Utada et al., 2010a: 2010b). An APC model considers three effects on incidence or mortality rate; age, period and cohort effects. Ito et al. (2011) calculated these three effects by using cancer incidence data for the 1968-2003 periods from the Osaka Cancer Registry and cancer mortality data for the 1968-2007 periods from vital statistics. We applied these age, period and cohort effects of cancer incidence and mortality in Osaka (Ito et al., 2011) and predicted these three effects as described below.

The age effects were estimated, in 5-year intervals, for the ages 40-94 for many sites and for the ages 20-94 for the other sites. The age effects for people under 39 or 19 were projected by linear extrapolations, and the 95-99 age effect was considered the same as the 90-94 age effect. The cohort effects were fixed in the same way as in the Cancer Statistics Report 2004 (CSR2004) (Ohno et al., 2004). That is, the estimated value for the birth cohort that most recently entered the age of cancer onset was used.

The period effects were examined by using the following 11 scenarios in the same way as in the previous study (Utada et al., 2010a). The scenarios are labeled by combinations of abbreviations indicating the order of the fitting function (Constant: C, linear: L, quadratic: Q), the period for fitting examination (only the latest year: I, latest previous 5 years: V, and latest previous 10 years: X) and the year assumed to be stable; that is, the year the slope became zero (2020: 20, 2030: 30).

(CI20) The period effect was fixed for the latest year.
(CV20) The period effect was fixed for the mean value
for the latest previous 5 years.

(CX20) The period effect was fixed for the mean value for the latest previous 10 years.

(LV20) Linear functions were applied for the period effects of the previous 5 years, and quadratic functions that were tangent to the linear function at the newest year and showed the turning point in 2020 were determined. The period effects after 2020 were stable.

(LX20) Linear functions were applied for the period effects of the previous 10 years, and the rest were calculated the same way as in scenario LV20.

(QV20) Quadratic functions were applied for the period effects of the previous 5 years, and quadratic functions that were tangent to the function at the newest year and showed the turning point in 2020 were determined. The period effects after 2020 were stable.

(QX20) Quadratic functions were applied for the period effects of the previous 10 years, and the rest were calculated the same way as in scenario QV20.

(LV30) Linear functions were applied for the period effects of the previous 5 years, and quadratic functions that were tangent to the function at the newest year and showed the turning point in 2030 were determined.

(LX30) Linear functions were applied for the period effects of the previous 10 years, and the rest were calculated the same way as in scenario LV30.

(QV30) Quadratic functions were applied for the period effects of the previous 5 years, and quadratic functions that were tangent to the function at the newest year and showed the turning point in 2030 were determined.

(QX30) Quadratic functions were applied for the period effects of the previous 10 years and the rest were calculated the same way as in scenario QV30.

Using these age, cohort and 11 scenarios for period effects, we calculated 11 estimated incidence and mortality rates until 2030 by age group for both sexes and for each sex.

The Osaka population data used for estimation was calculated by linear interpolation of 5-year interval values reported by the National Institute of Population and Social Security Research (2009). The estimated number of people aged 90 or over was reported as one group, and we considered 80% of this group to be 90-94 years old and 20% to be 95 or older.

Using this population data and three effects, we calculated the numbers of incident and mortality cases until 2030 for cancers at all sites and at selected sites.

**Selection of the prediction method**

We compared 11 estimated incidences and mortalities cases with observed incidence and mortality in order to evaluate the prediction method. For incidence, the sums of squares of the errors of the cancer incidence reported by the Osaka Cancer Registry from 2004 to 2005 were calculated, and the methods showing the smallest differences were selected as the most appropriate prediction methods. For mortality, the sums of squares of the errors of the cancer mortality reported by vital statistics from 2008 to 2009 were calculated, and the most appropriate prediction methods were selected in the same way as for incidence.

**Results**

**Population composition**

Regarding the population composition of Osaka in 2000 (observed) and 2030 (estimated), the population is expected to have decreased from 8,789,354 in 2000 to 7,740,941 in 2030, and the proportion of elderly people aged 65 or more is expected to have increased from 15% in 2000 to 31% in 2030.

**Incidence**

Table 1 shows the prediction methods used in this study. The prediction methods for the corpus uteri, cervix and uterus NOS including CIS, and cervix and uterus NOS were not selected in the way described above. The reported number of incidences in these three sites has increased rapidly since 2004, so very rapidly increasing estimated incidences were selected. This rapid increase is quite

| ICD-10 code | Incidence | Mortality |
|-------------|-----------|-----------|
| Both Sexes  |           |           |
| All sites*  | C00-96, D00-D09 | LV20 | - |
| All sites   | C00-96   | LV30 | LX30 |
| Esophagus   | C15      | LV20 | LX30 |
| Stomach     | C16      | QV20 | HX20 |
| Colon       | C18      | LV30 | QX30 |
| Rectum      | C19-20   | LX20 | LX30 |
| Colon & Rectum | C18-20 | QV20 | QX30 |
| Liver       | C22      | QX30 | LV30 |
| Gallbladder | C23-24   | QX30 | QX30 |
| Pancreas    | C25      | QV20 | QX30 |
| Lung        | C33-34   | QV20 | LX30 |
| Kidney      | C64-66, C68 | HV20 | HX20 |
| Urinary Bladder | C67   | QV30 | LX30 |
| Malignant Lymphoma | C81-85,96 | HX20 | HX20 |
| Male        |           |           |
| All sites*  | C00-96, D00-D09 | QX30 | - |
| All sites   | C00-96   | LV30 | LX30 |
| Esophagus   | C15      | HX20 | LX30 |
| Stomach     | C16      | QV30 | HX20 |
| Colon       | C18      | LV30 | QX30 |
| Rectum      | C19-20   | LX20 | LX30 |
| Colon & Rectum | C18-20 | QV20 | QX30 |
| Liver       | C22      | QX30 | LX30 |
| Lung        | C33-34   | QX30 | LX30 |
| Prostate    | C61      | QX30 | QX30 |
| Malignant Lymphoma | C81-85,96 | QV20 | HX20 |
| Female      |           |           |
| All sites*  | C00-96, D00-D09 | QX30 | - |
| All sites   | C00-96   | QV20 | HV20 |
| Esophagus   | C15      | HX20 | HX20 |
| Stomach     | C16      | QV30 | HX20 |
| Colon       | C18      | LV30 | QX30 |
| Rectum      | C19-20   | LX20 | LX30 |
| Colon & Rectum | C18-20 | QV20 | QX30 |
| Liver       | C22      | QX30 | QX30 |
| Lung        | C33-34   | QV20 | LX30 |
| Breast†     | C50      | LX30 | - |
| Breast‡     | C50      | LX20 | HX20 |
| Corpus Uteri| C54      | QV20 + LV30 | LX20 |
| Cervix + Uterus NOS* | C53, C55 | QV30 + QV20* | - |
| Ovary       | C56      | HX20 | HX20 |
| Malignant Lymphoma | C81-85,96 | HX20 | HX20 |

*Includes CIS, †Estimated period effect was zero, †Selected method by the way describing in Materials and Methods (left) and finally selected method (right).
Figure 2 shows the time trends of incident cases of age groups (0-64, 65-74, 75-84, 85+). All sites, stomach, lung, liver, and colon and rectum were examined according to sex, and breast and prostate were examined for females and males, respectively. For all sites, the estimated number of incident cases and the proportion of people aged 75 or older (especially 85 or older) are expected to increase. For five major cancers except for breast and prostate cancer, approximately 80% or more of incident cases are elderly aged 75 or older (especially 85 or older) are expected to increase. For males lung is expected to be the most common cancer site, followed in turn by stomach, colon and rectum, prostate, and liver. For females breast is expected to be the most common cancer site, followed in turn by colon and rectum, lung, stomach, and liver. The incident cases estimated in this study are closer to the observed data from the Osaka Cancer Registry than those estimated in the previous study. For liver only is the number of incident cases estimated in this study consistently larger than that estimated in the previous study.

Figure 2 shows the time trends of incident cases of age groups (0-64, 65-74, 75-84, 85+). All sites, stomach, lung, liver, and colon and rectum were examined according to sex, and breast and prostate were examined for females and males, respectively. For all sites, the estimated number of incident cases and the proportion of people aged 75 or older (especially 85 or older) are expected to increase. For five major cancers except for breast and prostate cancer, approximately 80% or more of incident cases are elderly aged 65 or older in 2030. The proportion of people aged 75 or older (especially 85 or older) are expected to increase. For males lung is expected to be the most common cancer site, followed in turn by stomach, colon and rectum, prostate, and liver. For females breast is expected to be the most common cancer site, followed in turn by colon and rectum, lung, stomach, and liver. The incident cases estimated in this study are closer to the observed data from the Osaka Cancer Registry than those estimated in the previous study. For liver only is the number of incident cases estimated in this study consistently larger than that estimated in the previous study.
five major cancers and prostate cancer that were calculated using the most appropriate method. For both sexes the site of most cancer predicted to occur most in 2030 is lung, followed in turn by stomach, colon and rectum, and liver. For males lung is expected to be the most common cancer site, followed in turn by stomach, colon and rectum, liver, and prostate. For females lung is expected to be the most common cancer site, followed in turn by stomach, colon and rectum, liver, and breast.

Figures 4 shows the time trends of mortality cases of age groups (0-64, 65-74, 75-84, 85+). For all sites, the estimated number of mortality cases and the proportion of people aged 75 or older (especially 85 or older) are expected to increase. For five major cancers except for breast and prostate cancer, 85% or more of mortality cases are elderly people aged 65 or older in 2030. Especially for prostate cancer, 97% are elderly people. The proportion of people aged 75 or older (especially 85 or older) are expected to increase, especially for prostate and lung.

Table 3 shows the time trends of age-standardized mortality rates. For many sites the expected age-standardized mortality rates have decreased, especially
Ito et al. (2011) reported that the cohort effect of incidence estimated by this study reflects this situation. In addition, with liver cancer. The large number of liver cancer cases estimated are larger than those estimated in the previous study. Osaka has large number of patients with viral hepatitis, which often causes liver cancer (Tanaka et al., 1998). We therefore think that Osaka has many patients aged 75 or older have increased. These tendencies could be a result of population aging. Comparing the results of the present study with those of our previous study (Utada et al., 2010b), which was based on incidence data for all Japan, we found liver is the only site for which the numbers of incident cases estimated are larger than those estimated in the previous study. Osaka has large number of patients with viral hepatitis, which often causes liver cancer (Tanaka et al., 1998). We therefore think that Osaka has many patients with liver cancer. The large number of liver cancer cases estimated by this study reflects this situation. In addition, Ito et al. (2011) reported that the cohort effect of incidence and mortality for liver among both male and female in Osaka peaked with the birth cohort in the early 1930’s and decreased immediately. As a result, the incidence and mortality of liver has decreased. In addition, Tsukuma et al. (2005) reported that prevalence of hepatitis C virus is high in the generation born around 1935 and is lower in younger generations. This is consist with our results.

We think that the number of incident cases estimated in the present study reflects the characteristics of Osaka, which were not considered in the previous study based on data for the whole of Japan. We recommend that the estimation of the number of incident cases in each prefecture based on the population-based cancer registry. We thus need to pay close attention to the completeness of the population-based cancer registry. As for the Osaka Cancer Registry, the percentage of cases registered by death certificate only (DCO) was improved during recently two decades (Osaka Medical Center for Cancer and Cardiovascular Disease, 2010; Ito et al., 2011), and the completeness of registry is considered to be improved. It is necessary to observe the changes in incidence continuously.

In conclusion, this is the first report in which estimated numbers of incidence and mortality cases and the proportion of people who died of cancer in Osaka, Japan: Future Trends Estimation. Cancer Incidence and Mortality in Osaka, Japan: Future Trends Estimation.
of cancer reflect prefecture characteristics. We believe these estimates would be useful in the planning and evaluation of cancer control activities in Osaka.

Acknowledgements

This study was supported by Grant-in-Aid for Scientific Research B (21310093) and a Cooperative Research from the Institute of Statistical Mathematics.

References

Ito Y, Ioka A, Nakayama T, Tsukuma H, Nakamura T (2011). Comparison of trends in cancer incidence and mortality in Osaka, Japan, using an age-period-cohort model. Asian Pac J Cancer Prev, 12, 879-88.

National Cancer Center (2006). Cancer Information Service, National Cancer Center. http://ganjoho.ncc.go.jp/public/statistics/pub/statistics04.html, Jul 6, 2010 access.

National Institute of Population and Social Security Research (2009). Population Projection for Japan. (http://www.ipss.go.jp/) Dec. 1.

Ohno Y, Nakamura T, Murata K, et al (2004). Prediction of cancer incidence in Japan. In ‘Cancer Statistics Report 2004’, Eds Oshima A, Kuroishi T, Tajima K. Shinohara Shuppan, Tokyo, 201-17.

Osaka Prefectural Department of Public Health and Welfare, Osaka Medical Association, Osaka Medical Center for Cancer and Cardiovascular Disease (2010). Annual Report of Osaka Cancer Registry No.73 – Cancer Incidence and Medical Care in Osaka in 2005 and the Survival in 2001-2003 –, OPDPHW.

Tanaka H, Tsukuma H, Hori Y, et al (1998). The risk of hepatitis C virus infection among blood donors in Osaka, Japan. J Epidemiol, 8, 292-6.

Tsukuma H, Tanaka H, Ajiki W, Oshima A (2005). Liver cancer and its prevention. Asian Pac J Cancer Prev, 6, 244-250.

Utada M, Ohno Y, Soda M, Kamo K (2010a). Estimation of cancer incidence in Japan with an age-period-cohort model. Asian Pac J Cancer Prev, 11, 1235-40.

Utada M, Ohno Y, Tatsumi Y, Soda M (2010b). Estimation of cancer incidence by Prefectures in Japan. Japanese J Applied IT Healthcare, 11, 1235-40.